PMID- 8049645
OWN - NLM
STAT- MEDLINE
DCOM- 19940902
LR  - 20191210
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 13
IP  - 3-4
DP  - 1994 Apr
TI  - Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, 
      and treatment.
PG  - 203-14
AB  - Patients with chronic lymphocytic leukemia (CLL) are at an increasing risk of 
      infectious morbidity and mortality. Infections are generally due to bacteria and 
      influenced by the degree of hypogammaglobulinemia; although, in more advanced 
      stages of disease they may also be contributed by neutropenia due to bone marrow 
      infiltration and/or cytotoxic therapy. Furthermore, defect in cell-mediated 
      immunity appears to be a predisposing factor to infections in patients treated 
      with newer purine analogues. Controversies surrounding the pathogenesis of 
      infectious complications in CLL raise several questions on their management. 
      Patients with advanced disease who receive cytotoxic therapy might qualify for 
      antibacterial prophylaxis. Intravenous immunoglobulin (IVIG), although of 
      scientific interest, may be of little relevance at the present time. The new 
      growth factors should be tested in well-designed prospective studies.
FAU - Molica, S
AU  - Molica S
AD  - Divisione di Ematologia, Ospedale Regionale A. Pugliese, Cantanzaro, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunologic Factors)
RN  - 9007-36-7 (Complement System Proteins)
SB  - IM
MH  - Actuarial Analysis
MH  - Agammaglobulinemia/complications/therapy
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Antimetabolites, Antineoplastic/adverse effects
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Bacterial Infections/epidemiology/etiology
MH  - Complement System Proteins/deficiency
MH  - Humans
MH  - Immunity, Cellular
MH  - Immunocompromised Host
MH  - Immunologic Factors/adverse effects/therapeutic use
MH  - Incidence
MH  - Infection Control
MH  - Infections/drug therapy/*epidemiology/etiology/therapy
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*complications/mortality/therapy
MH  - Lymphocyte Subsets/immunology
MH  - Neutropenia/complications
MH  - Risk Factors
MH  - Splenectomy/adverse effects
MH  - Survival Analysis
MH  - Vaccination
RF  - 117
EDAT- 1994/04/01 00:00
MHDA- 1994/04/01 00:01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 1994/04/01 00:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
AID - 10.3109/10428199409056283 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 1994 Apr;13(3-4):203-14. doi: 10.3109/10428199409056283.